Osteopenia Treatment Guidelines

Definition and Risk Assessment

The American College of Physicians recommends that risk assessment should include evaluation of fracture risk using tools such as FRAX to guide treatment decisions 1
Treatment decisions should be based on the 10-year risk of fracture rather than bone mineral density alone, as recommended by the American College of Physicians 2

The American College of Sports Medicine recommends regular weight-bearing exercise (30 minutes at least 3 days per week) for patients with osteopenia 1
The American Heart Association recommends tobacco cessation and limiting alcohol consumption for patients with osteopenia 3, 4
The Centers for Disease Control and Prevention recommends fall prevention strategies for those at risk of falls 4
The National Institutes of Health recommends calcium supplementation (1000-1500 mg daily) and vitamin D supplementation (800-1000 IU daily) for patients with osteopenia 1

The American College of Rheumatology recommends oral bisphosphonates (particularly risedronate) for osteopenic women 65 years or older at high risk of fracture (FRAX 10-year risk of hip fracture ≥3% or major osteoporotic fracture ≥20%) 5, 2
The American Society of Clinical Oncology recommends bisphosphonates or denosumab for cancer survivors with osteopenia and additional risk factors 3
The American College of Rheumatology recommends oral bisphosphonates for adults receiving high-dose glucocorticoids (≥30 mg/day of prednisone or equivalent) 6

The National Osteoporosis Foundation recommends repeat bone density scans every 2 years to monitor bone density in patients with osteopenia 3
The American College of Physicians recommends against performing bone density scans more than annually 3
The American College of Physicians recommends against bone density monitoring during the initial 5-year treatment period for patients on pharmacologic therapy 7

The American College of Physicians recommends treatment duration of typically 5 years for patients who initiate pharmacologic therapy 7
The American College of Physicians recommends reassessment of fracture risk after 5 years to guide decisions about continuing or discontinuing therapy 7

The American College of Physicians recommends against overtreatment of low-risk patients and undertreatment of high-risk patients with osteopenia 2
The American College of Rheumatology recommends special considerations for women of childbearing potential regarding bisphosphonate therapy due to potential fetal harm 6

The patient has osteopenia with a T-score of -1.7 at the right femoral neck and -0.7 at the lumbar spine, according to the Journal of the American College of Radiology guidelines 8
The National Osteoporosis Foundation (NOF) recommends treatment thresholds of ≥20% for major osteoporotic fracture and ≥3% for hip fracture, which this patient does not meet 8

The National Osteoporosis Foundation (NOF) recommends treatment for postmenopausal women with a T-score at or below -2.5 at the femoral neck, total hip, or lumbar spine 8
Treatment is recommended for postmenopausal women with low bone mass (T-score between -1.0 and -2.5) AND a 10-year probability of major osteoporotic fracture ≥20% OR hip fracture ≥3% based on FRAX, according to the American College of Radiology and Journal of Clinical Oncology guidelines 8, 9
A history of hip or vertebral fracture is also an indication for treatment, as recommended by the Journal of Clinical Oncology 9

Earlier reassessment of bone density may be warranted if new risk factors develop, according to the Journal of the American College of Radiology guidelines 8
The FRAX tool has been validated in large U.S. cohorts and is considered reliable for guiding treatment decisions, as stated by the American Academy of Family Physicians 10